J&J dumps PhII-ready CD28 au­toim­mune as­set, re­turns rights to French part­ner

7 years ago
Pharma

Ex­perts ques­tion Amar­in's ear­ly tout­ing of Vas­cepa da­ta ahead of de­tailed re­sults

7 years ago
R&D

Sun Bio­Phar­ma founder Michael Cullen steps up; Se­maThera set­tles on per­ma­nent CEO; On­coSec nabs Kel­lie Mal­loy Fo­ert­er ...

7 years ago
Peer Review

Tun­ing in: In­ten­si­ty's im­mune-based chemo de­liv­ery tech at­tracts back­ing of British bil­lion­aire Jim Mel­lon

7 years ago
Financing
Startups

Il­lu­mi­na forks out $1.2B to buy ri­val Pa­cif­ic Bio­sciences, plac­ing long and short-read DNA tech un­der the same roof

7 years ago
Pharma

FDA ex­perts gun down Alk­er­mes’ pitch for ALKS-5461, slam­ming the com­pa­ny on mul­ti­ple fronts

7 years ago
Pharma

Urovan­t's over­ac­tive blad­der drug scores in mid-stage tri­al

7 years ago
R&D

Ver­tex wins third CF ap­proval in Eu­rope; ERS Ge­nomics grants Defini­GEN ac­cess to CRISPR/Cas9 tech

7 years ago
News Briefing

FDA preps for a new and flex­i­ble ap­proach to genome edit­ing in an­i­mals

7 years ago
Pharma

Climb­ing the block­buster moun­tain, Roche/Ab­b­Vie team her­alds a win in front­line CLL PhI­II

7 years ago
R&D

GW's cannabis-de­rived drug Epid­i­olex fi­nal­ly launch­es in the US with an av­er­age list price of $32,500

7 years ago
Pharma

As ri­vals press in, Stan­ford spin­out Forty Sev­en bur­nish­es its prospects from an im­pres­sive PhIb

7 years ago
R&D

6 months af­ter ar­riv­ing at Sanofi R&D, John Reed gam­bles $125M on De­nali’s RIPK1 work

7 years ago
Pharma

Tonix jumps on re­jigged phase III for PTSD drug; MeiraGTx scores an­oth­er NIH deal; Op­Gen, Qi­a­gen join hands to de­tect ...

7 years ago
News Briefing

FDA staff sug­gests safe­ty pro­file of Sage post­par­tum de­pres­sion drug dis­qual­i­fies it from at-home in­fu­sions

7 years ago
Pharma

Weeks af­ter launch­ing Aeter­na Zen­taris castoff, Strong­bridge turns around and sells rights to No­vo Nordisk — at a ...

7 years ago
Pharma

Gilead throws its weight — and $50M cash — be­hind Tan­go's I/O dis­cov­ery en­gine

7 years ago
Discovery

GSK toss­es a trio of clin­i­cal-stage drugs on tri­al fail­ures, win­now­ing out its res­pi­ra­to­ry pipeline as can­cer moves ...

7 years ago
R&D

Aca­dia says Nu­plazid cleared main goal in de­pres­sion study, but da­ta ap­pear mixed

7 years ago
R&D

Gene ther­a­py de­vel­op­er Or­chard prices IPO at $14 to raise $200M

7 years ago
Financing
Cell/Gene Tx

Fi­nal­ly! In­novent hikes on Hong Kong de­but amid cloudy mar­ket sen­ti­ments

7 years ago
Financing
China

Feds charge a group of Genen­tech vets with an­oth­er scheme to steal trade se­crets — this time to help a Tai­wanese ...

7 years ago
China

The next big thing at Glax­o­SmithK­line R&D is clear­ly on­col­o­gy — res­pi­ra­to­ry can take a back seat now

7 years ago
R&D

Roche adds $25M to Halozyme pact for fresh tar­gets; FDA OKs car­dio in­di­ca­tion for J&J's In­vokana

7 years ago
News Briefing
First page Previous page 988989990991992993994 Next page Last page
A service from the Financial Times